I was just looking through my blog and realised I have not posted about Calista here.
Calista Therapeutics are developing medications that target F508del. Pre clinical studies are underway and they are looking for funding for a phase 2a trial.
The lead candidate is Procaftor, which appears to work to about 116% of VX809 (see the graph). I've added more info and the graph here: http://sixtyfiverosesblog.wordpress.com/2013/06/20/calista-therapeutics-f508del-research/
Calista Therapeutics are developing medications that target F508del. Pre clinical studies are underway and they are looking for funding for a phase 2a trial.
The lead candidate is Procaftor, which appears to work to about 116% of VX809 (see the graph). I've added more info and the graph here: http://sixtyfiverosesblog.wordpress.com/2013/06/20/calista-therapeutics-f508del-research/